Immuno-Oncology Therapies: In-Depth Analysis of the Rapidly Evolving Landscape in Next-Generation Cancer Treatment
21 Mar 2024
ImmunotherapyVaccineCell TherapyASCOAACR
DUBLIN , March 20, 2024 /PRNewswire/ -- The "Innovation Waves in Immuno-oncology Therapy Development" report has been added to
ResearchAndMarkets.com's offering.
Immuno-oncology (I-O) therapies target tumors by harnessing the host's immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy.
Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.
Key questions answered in this study:
What does the current clinical landscape of I-O therapies look like?
Which are the technology enablers driving the adoption of I-O therapies?
What are the key developments in adoptive cell therapies and cancer vaccines?
What are the roadblocks to successful translation?
What are the research and development (R&D) focus areas?
What are the key focus areas for the future?
Key Growth Opportunities
Growth Opportunity 1: Combination Immunotherapies
Growth Opportunity 2: Precision Oncology
Growth Opportunity 3: Advanced Synthetic Biology Platforms
Growth Opportunity 4: Organoids and Organ-on-Chip Models
Key Topics Covered:
Growth Environment: I-O Therapies
Need for Immunotherapy
Scope of Analysis
Segmentation: Snapshot of I-O Therapies
I-O Therapies in Development
Growth Opportunities in I-O Therapy
Growth Drivers
Growth Restraints
Trends and R&D Focus: I-O Therapies
I-O Technology Trends and Developments
Trends in I-O Therapeutics
Therapeutic Development Trends in I-O
R&D Focus Areas to Boost Immunotherapies
Modulation of TME: Solid Tumor Type Determines Therapy
Developing Effective Preclinical Models for Translation
Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
Holistic Tumor Profiling to Boost Precision Oncology Efforts
Emerging I-O Therapeutic Modality Development Landscape
Quick Facts on I-O Therapies
Clinical Development Landscape of I-O Therapies
Cell Therapy to Create the Next Wave of I-O Developments
Cell Therapy Types: Snapshot
Clinical Development Landscape of I-O Cell Therapies
Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
Next-generation CAR-T Therapy Development
Priority Areas to Improve the Accessibility of Cell Immunotherapy
Innovative Technologies for Cell Therapy Manufacturing and Delivery
Stakeholders Developing Emerging Next-gen Cell Therapies
Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
Cancer Vaccine Types
Personalized Neoantigen Vaccines in Clinical Development
Areas of Focus to Bolster Cancer Vaccine Development
RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
Road Ahead for Cancer Vaccines and Immunotherapy
Emerging Cancer Vaccine
I-O Stakeholder Ecosystem
Regional Trends in I-O Developments and Adoption
Federal Initiatives and Programs Driving I-O Therapy Development
I-O Deals and Investment Trends
Notable Partnerships and Collaborations in I-O, 2023
I-O Regulatory Environment and Reimbursement
I-O: Current Gaps and Potential Opportunities
Strategies to Improve Access and Care Delivery of I-O Therapies
For more information about this report visit https://www.researchandmarkets.com/r/9og2f0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.